An alternative 2/1 dosing schedule of sunitinib may improve tolerability, reduce the
number of dosing changes or discontinuation, and improve clinical outcomes in
patients with metastatic renal cell carcinoma (mRCC), a new study shows.
Up to 50% of patients with mRCC experience adverse events and require dose reductions with the approved dosing schedule of sunitinib (Sutent, Pfizer), which consists of 50 mg daily for four weeks, followed by a two-week rest (4/2 schedule), and as many as